Momenta Pharmaceuticals
Momenta Pharmaceuticals was a Cambridge-based biotechnology company developing novel and biosimilar biologics for autoimmune and neurological disorders. Acquired by Johnson & Johnson in August 2024 for $6.5 billion, it now operates as a J&J subsidiary.
- Company typePrivate
- Founded2001
- HeadquartersCambridge, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Momenta Pharmaceuticals does
Momenta Pharmaceuticals was a biotechnology company specializing in the characterization and process engineering of complex molecules, with a therapeutic focus on novel biologics for autoimmune diseases and neurological disorders. Founded in 2001 and headquartered in Cambridge, Massachusetts, the company developed both novel biologic therapeutics and biosimilar candidates in immunology and neuroscience, including programs targeting the FcRn pathway. The company's underlying technology centered on proprietary analytical and process capabilities for complex biologics, which underpinned both its biosimilar development efforts and its novel pipeline.
The business model was that of a development-stage biopharmaceutical company: capital was raised through equity financings (with rounds of $19 million in 2003, $20.5 million in 2004, and $49 million in 2009) and deployed into R&D rather than commercial sales. Customer-facing exposure was limited to pipeline-stage assets targeting patients with autoimmune and neurological conditions, with no named commercial products or distribution channels disclosed in the available data. Strategic expansion was pursued through targeted acquisitions, including Parivid in 2007 and Virdante Pharmaceuticals in 2011, to broaden biologics capabilities.
In August 2024, Johnson & Johnson acquired Momenta for approximately $6.5 billion, after which the company ceased independent operations and became a wholly-owned subsidiary of J&J. Post-acquisition, Momenta's pipeline and research capabilities are being deployed within J&J's larger pharmaceutical organization, providing access to global commercial infrastructure that the standalone entity lacked.
Momenta Pharmaceuticals firmographics
Firmographics- Name
- Momenta Pharmaceuticals
- Website
- https://momentapharma.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Momenta Pharmaceuticals was a Cambridge-based biotechnology company developing novel and biosimilar biologics for autoimmune and neurological disorders. Acquired by Johnson & Johnson in August 2024 for $6.5 billion, it now operates as a J&J subsidiary.
- Ownership category
- akta.pro rank
Momenta Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Momenta Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Momenta Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Momenta Pharmaceuticals product offering
Product offeringCore offering
Momenta Pharmaceuticals was a biotechnology company that specialized in the characterization and process engineering of complex molecules to develop novel biologics and biosimilars. Its pipeline targeted autoimmune diseases and neurological disorders, with particular emphasis on FcRn-pathway and related immunology programs. Following its August 2024 acquisition by Johnson & Johnson, the company operates as a wholly-owned subsidiary of J&J.
Product overview
Momenta Pharmaceuticals was a biopharmaceutical company that developed novel and biosimilar biologic drugs, focused on immunology and neuroscience therapeutic areas. The company was acquired by Johnson & Johnson in August 2024 for approximately $6.5 billion. As an independent entity, Momenta operated its drug discovery and development pipeline; specific named products or product portfolio details are not present in the provided sources.
Differentiator
Problem solved
Functional benefit
Companies that use Momenta Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles2 records
Momenta Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Momenta Pharmaceuticals partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
Momenta Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Immunovant: Immunovant develops FcRn-targeted antibodies (batoclimab, IMVT-1401) across autoimmune indications, directly overlapping Momenta's FcRn pipeline strategy and competing for the same patient populations.
- Samsung Bioepis: Samsung Bioepis is a major biosimilars developer (Remicade, Enbrel biosimilars) — Momenta was one of the few other US-based players with comparable biosimilar and biologic process-engineering capability.
- UCB: UCB is a biopharma focused on immunology (Cimzia, Rystiggo) and neurology — overlapping both pillars of Momenta's therapeutic focus and competing in FcRn and other autoimmune biologics.
- Argenx: Argenx is the leading FcRn antibody developer (Vyvgart franchise), the most direct mechanistic competitor to Momenta's FcRn programs and the benchmark for autoimmune biologics valuation in this space.
- Alvotech: Alvotech is a biosimilars pure-play focused on complex biologics including autoimmune mAbs — directly comparable to Momenta's historical biosimilar manufacturing/characterization capability.
Broad incumbents
- Horizon Therapeutics (Amgen): Amgen's acquisition of Horizon Therapeutics in 2023 for ~$28B validated autoimmune/rare-disease pipeline assets of the kind Momenta developed, making it the closest comparable M&A precedent.
- Alexion / AstraZeneca Rare Disease: Alexion pioneered anti-complement biologics (Soliris/Ultomiris) in autoimmune rare disease and represents the established large-pharma playbook for monetizing immunology biologics — comparable to what J&J hopes to replicate with Momenta's pipeline.
- BioMarin Pharmaceutical: BioMarin is a biologics-focused rare-disease company with comparable scientific depth in complex-molecule manufacturing and autoimmune-adjacent indications.
- AbbVie: AbbVie's Humira/Skyrizi/Rinvoq franchise defines the autoimmune biologics market; its immunology commercial machine sets the benchmark J&J targets by absorbing Momenta's pipeline.
- Janssen / Johnson & Johnson Innovative Medicine: J&J's pharma arm is now Momenta's parent and operating integrator; its Tremfya/Stelara immunology franchise provides the commercial chassis that determines forward value capture from Momenta's pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Momenta Pharmaceuticals social profiles
Digital presenceMomenta Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Momenta Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Momenta Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Momenta Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Momenta Pharmaceuticals
What does Momenta Pharmaceuticals do?
Momenta Pharmaceuticals was a biotechnology company that specialized in the characterization and process engineering of complex molecules to develop novel biologics and biosimilars. Its pipeline targeted autoimmune diseases and neurological disorders, with particular emphasis on FcRn-pathway and related immunology programs. Following its August 2024 acquisition by Johnson & Johnson, the company operates as a wholly-owned subsidiary of J&J.
Is Momenta Pharmaceuticals a public or private company?
Momenta Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Momenta Pharmaceuticals founded?
Momenta Pharmaceuticals was founded in 2001. It employs 501 to 1,000 people.
Where is Momenta Pharmaceuticals based?
Momenta Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.
Who are Momenta Pharmaceuticals's main competitors?
Direct peers on record are Immunovant, Samsung Bioepis, UCB, Argenx and Alvotech. Broad incumbents are Horizon Therapeutics (Amgen), Alexion / AstraZeneca Rare Disease, BioMarin Pharmaceutical, AbbVie and Janssen / Johnson & Johnson Innovative Medicine.
Does Momenta Pharmaceuticals have an API?
No public API is recorded for Momenta Pharmaceuticals.
What industry is Momenta Pharmaceuticals in?
Momenta Pharmaceuticals's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.